DrugDashboards

Gemfibrozil

Gemfibrozil · GEMFIBROZIL 600 mg/1 · Tablet, Film Coated · Oral · Chartwell RX, LLC

NDC 62135-0160-60 · 60 TABLET, FILM COATED in 1 BOTTLE · ANDA · View full market →

The short version

10 companies supply this market — deep enough that no single failure threatens the supply. The price has held steady around $0.1045 per unit over the past year. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$0.1045per EAinvoice-surveyed acquisition cost · Aug 19, 2026
  • Part D plans paid (avg)$0.1592per dosage unitgross, before rebates — matched by drug name · 2024
  • Medicaid generic ceiling (FUL)$0.1062per TABweighted avg manufacturer price $0.0607 · Aug 1, 2026102% of what pharmacies pay — higher than 57% of drugs with this benchmark

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 00071-0737-20) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$1.30per unit
middle half $1.30$1.30 · 2 plans · Jan 1, 2026
Est. net of rebates
≈ $1.30
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
0%of plans cover it
tier 1 · prior auth 0% · step therapy 0% · qty limit 100%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 9 quarters since 2024.

NADAC price per unit

$0$0.05$0.1$0.15Sep 2024Sep 2026$0.1045
25 price points · per EA · dashed = manufacturer avg (WAMP)Source: CMS NADAC

Estimated fill cost

#30 count
$3.14
#90 count
$9.41

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Supply fragility

0Low risk

Nothing here is signaling trouble: several manufacturers, no current shortage, no recent serious recalls, stable pricing. In drug supply, boring is the good outcome.

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for gemfibrozil (oral solid) in the next 90 days

sole-source market · price up 2% YoY

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Regulatory

Application
ANDA074270
TE code
AB
Approval date
Sep 27, 1993
Patents / exclusivity
None on file

Shortage history

  • Planned discontinuation Lopid, Tablet, 600 mg (NDC 0071-0737-20)Feb 10, 2026

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Gemfibrozil (Tablet, Film Coated)

LabelerStrengthFirst seenLast seen
A-S Medication SolutionsGEMFIBROZIL 600 mg/1Jul 15, 2026Sep 3, 2026
Aphena Pharma Solutions - Tennessee, LLCGEMFIBROZIL 600 mg/1Jul 15, 2026Sep 3, 2026
Bryant Ranch PrepackGEMFIBROZIL 600 mg/1Jul 15, 2026Sep 2, 2026
Chartwell RX, LLCGEMFIBROZIL 600 mg/1Jul 15, 2026Sep 2, 2026
Exelan Pharmaceuticals, Inc.GEMFIBROZIL 600 mg/1Jul 15, 2026Sep 2, 2026
NCS HealthCare of KY, LLC dba Vangard LabsGEMFIBROZIL 600 mg/1Jul 15, 2026Sep 2, 2026
NorthStar Rx LLCGEMFIBROZIL 600 mg/1Jul 15, 2026Sep 2, 2026
Parke-Davis Div of Pfizer IncGEMFIBROZIL 600 mg/1Jul 15, 2026Sep 2, 2026
Rising Pharma Holdings, Inc.GEMFIBROZIL 600 mg/1Jul 15, 2026Sep 2, 2026
Aurobindo Pharma LimitedGEMFIBROZIL 600 mg/1Jul 15, 2026Aug 31, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Gemfibrozil — NDC 62135-0160-60," retrieved September 3, 2026, https://drugdashboards.com/drug/62135016060.

Free to cite with attribution — see how the data is put together.